Devens, MA, USA — Veranova is pleased to announce the appointment of Dr. Matteo Villain as Vice President of Peptides and Oligonucleotides. Dr. Villain will bring extensive expertise in peptide and oligonucleotide development and manufacturing to Veranova as the company continues to strengthen its position as a key player in the Peptide and Oligonucleotide (TIDES) space.
“Dr. Villain, and his holistic experience in the development and manufacturing of peptide APIs, will be a tremendous asset to Veranova,” says Rohtash Kumar, Senior Vice President of Development Operations and Chief…
Amsbio, in association with Nordmark Biochemicals, has expanded its range of Collagenase and Neutral Protease NB enzymes with GMP grade formats and protocols to support advanced tissue dissociation workflows for applications from research to clinical use.
These enzymes, derived from Clostridium histolyticum, are critical raw materials for isolating viable cells from complex tissues - an essential step in tissue engineering, cell therapy and regenerative medicine. Their clinical relevance is reinforced by recent studies to set up a protocol for isolation, manufacturing, and…
Financing led by Ahren Innovation Capital with additional investment from Kadmos Capital, Empirical Ventures and Panacea Ventures
Investment to leverage OutSee’s proprietary AI-based predictive genomics technology, Nomaly, to expand and progress in-house target development program
Cambridge, UK, 24 June 2025: OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced it has secured £1.8M in seed funding, led by Ahren Innovation Capital and with additional investment from Kadmos Capital, Empirical…
The June edition of our People Pathways newsletter is available to read here!
Featuring:
✅ One Nucleus upcoming courses
✅ Training Course Spotlight: Introduction to Drug Development
✅ Practical Application of Toxicology in Drug Development 2025
Gastronomica, Pioneer Group’s cutting-edge food tech hub, was crowned winner of the Innovative Workplace Design award at the Property Week and Construction News Life Sciences & Research Clusters Awards.
The Awards celebrated excellence in real estate design and delivery across the life sciences and research sectors, with winners announced at a gala evening at the Hilton Bankside, London on 24 June 2025.
Chosen from a strong field, the judges praised Gastronomica’s clear vision to create a purpose-built cluster featuring sector-specific workspaces. They highlighted the hospitality-inspired…
Creative Biolabs stands as a powerhouse of antibody engineering expertise, whose end-to-end humanization platform is turning xenogeneic antibodies into preclinical frontrunners.A Ludwig Cancer Research team has cracked a metabolic code tumors use to evade immune attack, unveiling a humanized antibody that reignites anti-cancer immunity in resistant liver cancers, which was published in Cancer Discovery. The CD36-blocking antibody PLT012 overcomes lipid-driven immunosuppression, which is a game-changer for tumors exploiting fatty microenvironments. The breakthrough underscores a…
Sandwich, UK - 23 June 2025: Discovery Park opened its doors for the East Kent Science Jamboree, hosting a record-breaking 1,500 children from 51 Kent schools for a two day science spectacular.
This year's 30th anniversary celebration was the largest ever jamboree and marked a decade of the summit taking place at Sandwich science hub Discovery Park. Led by the STEM Hub at Canterbury Christ Church University and supported by Pfizer, the inspirational day introduced school pupils to science in action and demonstrated how STEM subjects impact everyday life.
The three-decade long science…
June 19, 2025
Devens, MA, USA — Government officials, industry leaders, and local business representatives gathered yesterday to mark the groundbreaking of Veranova’s latest expansion at its Devens, Massachusetts facility.
First announced in June 2024, the investment will add 9,000 square feet to the site, including a new state-of-the-art process development laboratory and two current Good Manufacturing Practice (cGMP) suites. These new capabilities will expand the site’s development and production capabilities for potent compounds, ADC linker-payloads, and other complex molecules critical to…
Amsbio announces an innovative range of Induced Pluripotent Stem Cell (iPSC) kits for researchers requiring a rapid, reproducible, and scalable means of generating specific neural cell types without sacrificing cell purity.
These kits use simple, highly reproducible protocols to ensure experimental consistency. These streamlined protocols allow researchers to efficiently differentiate iPSCs into target neural cells within just 1-2 weeks. Scientists can now produce neurons as needed, ensuring greater flexibility and control in design of disease modelling, regenerative medicine, and drug…
Mursla Bio Introduces AI Precision Medicine Platform Built on Organ-Specific EV Isolation from Blood
Platform is built on biologically labelled, organ-specific multi-omics data carried by extracellular vesicles isolated from 2ml plasma samples
Enables differentiated AI-powered biomarker discovery and IVD translation for patient stratification, therapeutic monitoring, surrogate markers and other diagnostic development programs
Publication of pre-print data, with support from Evotec International GmbH and University College London demonstrates validation of Platform’s capability for liver diseases
Cambridge, UK, and Boston MA, USA, 17 June 2025: Mursla Bio, a leader in Extracellular…